Pharmaceutical GMP Readiness in China
China's drug framework is set by the Drug Administration Law (2019 revision) and the Provisions for Drug Registration (2020).
In Short
- NMPA sits under the State Administration for Market Regulation.
- The MAH (Marketing Authorization Holder) system, introduced nationally in 2019, separates the licence holder from the manufacturer.
- China operates a national drug electronic supervision code (药品电子监管码) — a unique identifier on saleable packs reported through the NMPA hub for high-risk classes…
The National Medical Products Administration (NMPA) regulates drugs; the Center for Food and Drug Inspection (CFDI / NIFDC) conducts GMP inspections. China-GMP (2010, with subsequent revised annexes including the 2020 Annex on Data Integrity) is technically aligned with EudraLex Vol 4 / WHO TRS but is enforced independently — China is an ICH member since 2017 but is NOT a PIC/S member. Marketing requires an MAH established in China. This guide covers the China-specific layer.
Regulator and Legal Basis
NMPA sits under the State Administration for Market Regulation. CDE handles registration review; CFDI conducts GMP inspections; provincial MPAs license domestic sites.
More on regulator and Legal Basis
Statutory base: Drug Administration Law 2019; Provisions for Drug Registration 2020; 2010 GMP plus revised annexes (sterile, biologicals, APIs, TCM, IMPs, data integrity).
MAH System and Imported Drugs
The MAH (Marketing Authorization Holder) system, introduced nationally in 2019, separates the licence holder from the manufacturer. Foreign manufacturers cannot hold the MAH directly — they appoint a designated Chinese legal entity as the MAH agent.
More on mAH System and Imported Drugs
Imported drugs require an Imported Drug Licence (IDL) and on-site inspection of the foreign manufacturing site by CFDI.
Drug Code, Language, and Labelling
China operates a national drug electronic supervision code (药品电子监管码) — a unique identifier on saleable packs reported through the NMPA hub for high-risk classes (vaccines fully; broader categories being phased in). All labelling and IFU must be in simplified Chinese; submissions are in Chinese with English supporting allowed.
Inspection Style and Common Findings
CFDI inspections are intensive and often unannounced. Outcomes feed into licence retention and may trigger product recall.
More on inspection Style and Common Findings
Common findings: data integrity (the 2020 annex is enforced strictly), deviation/CAPA, sterile/Annex 1 equivalent contamination control, and supplier qualification of imported APIs. China is not in PIC/S — EU/US inspection reports are referenced but not formally relied upon.
A 90–180 day China readiness path
- Days 0–30
appoint MAH agent; identify IDL scope and product registrations.
- Days 31–90
align documentation to 2010 GMP and the data-integrity annex; prepare simplified Chinese labelling.
- Days 91–180
pre-inspection readiness with bilingual records; host CFDI inspection. Plan 6–18 months for full registration timelines.
Questions
Is China a PIC/S member?
Not as of 2026. China is an ICH member (since 2017) and has substantially converged on ICH guidelines, but NMPA inspections do not rely on PIC/S partners' GMP certificates — CFDI will inspect foreign sites for imported drugs.
Do we need a Chinese MAH or can we hold our own MA?
Foreign manufacturers cannot hold the MAH directly. A Chinese legal entity must hold the MAH role, with documented agreements covering quality oversight, pharmacovigilance, and recall responsibility.
How strict is China on data integrity?
Very. The 2020 Annex on Data Integrity codified ALCOA+ expectations; CFDI inspectors actively examine audit trails, instrument software user management, and contemporaneous records. Hybrid (paper + electronic) systems are a frequent finding area.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
The Pharmaceutical Operations Guide
Right material. Right record. Released by a person.
- Who decides, and who may not
- Supplier to finished bulk
- Test, review, investigate
- Packs, serialisation and recall
Plus Evidence map and four worksheets.
Get the pharmaceutical guideWe ask for your name and email so we can handle this request. The full guide then opens on this site, ready to translate, print or save. Privacy policy. Practical orientation, not legal advice; your quality unit decides which rules apply.
UltimateFree guide
The Pharmaceutical Operations Guide
Right material. Right record. Released by a person.
Keep reading
Global Pharmaceutical GMP Readiness: Principles That Travel- Australia Pharmaceutical GMP Readiness: TGA and PIC/S GMP
Brazil Pharmaceutical GMP Readiness: ANVISA RDC 658/2022
Canada Drug GMP Readiness: Food and Drug Regulations Part C, Division 2
EU GMP Guide: EudraLex Volume 4 Chapters, Annexes and Who Decides
GCC Pharmaceutical GMP Readiness: Saudi SFDA and UAE